Last checked at 8 Apr 2021 07:00
Publication of Notice of Annual General Meeting and Annual Report
Dublin, London | 8 April 2021: Uniphar plc (the "Company" or "Uniphar") wishes to announce that it is today posting to shareholders its Notice of Annual General Meeting ("AGM") for 2021 together with its annual report and accounts for the year ended 31 December 2020 ("Annual Report"). The AGM will be held at 11.00 a.m. on 12 May 2021 at Uniphar's registered office, 4045 Kingswood Road, Citywest Business Park, Dublin 24, D24 V06K.
Uniphar considers the well-being of shareholders, employees and attendees a top priority. Based on the latest available guidance from the Health Service Executive ("HSE") in Ireland, the board of directors of Uniphar (the "Board") expect the AGM to proceed on 12 May 2021 but under very constrained circumstances. Given the severity of the circumstances and the health risks involved, Uniphar's directors will take all appropriate safety measures to ensure the safety of attendees and others involved in the AGM, including restricting attendance at the AGM, should it be deemed necessary or desirable.
The Notice of meeting, Form of Proxy, Annual Report and accounts are available to view on the Company's website at https://www.uniphar.ie/static/investors/shareholder-centre/AGM and will be available for inspection during normal business hours on any business day from today until the conclusion of the AGM at the registered office of the Company. In accordance with applicable regulations and public health guidelines in force in Ireland in connection with Covid-19, shareholders are requested not to physically attend the Company's registered office to inspect those documents and are instead requested to inspect those documents online.
Public Health Guidelines and the AGM
The Company is closely monitoring and adhering to public health measures prescribed by the Government of Ireland and the Department of Health relating to Covid-19. The Company has a legal obligation to hold this AGM, and while it is expected that the AGM will proceed as planned on 12 May 2021, it is likely to do so under very constrained circumstances. To avoid unnecessary risk to the Company's shareholders, employees and other attendees, the Company recommends shareholders to participate in the AGM by electronic means, including by casting their proxy votes electronically in advance of the meeting. Details of how to do so are set out in further detail in the Circular.
A listen only conference call facility will be provided to allow shareholders to listen to the business of the meeting. Please note that this facility will allow you to listen to the business of the AGM only, you will not be able to use this facility to vote, raise points or issues, ask questions or table resolutions. If you wish to listen live to the AGM proceedings, you can register for the conference call and receive participant log-in details at https://www.uniphar.ie/static/investors/shareholder-centre/AGM.
Shareholders availing of this facility should also ensure to submit their Form of Proxy by the relevant deadline in advance of the AGM, as it will not be possible to vote using the conference call facility.
Shareholders are invited to submit questions in writing in advance of the meeting either by email to companysecretary@uniphar.ie or by post to the Company Secretary, Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24 V06K, Ireland. Questions must be received by 11.00 a.m. on 10 May 2021. Shareholders must include their Shareholder Reference Number (as set out on their Form of Proxy) with any question submitted.
The Company continues to monitor the impact of Covid-19 and any relevant updates regarding the AGM, including any changes to the arrangements outlined in this Notice, will be announced via stock exchange announcement and will be available on https://www.uniphar.ie/static/investors/shareholder-centre/AGM.
In the event that it is not possible to hold the AGM either in compliance with public health guidelines or applicable law or where it is otherwise considered that proceeding with the AGM as planned poses an unacceptable health and safety risk, the AGM may be adjourned or postponed or relocated to a different time and/or venue, in which case notification of such adjournment or postponement or relocation will be given in accordance with applicable law.
For further details contact:
Uniphar | +353 (0) 1 428 7777 |
|
|
Brian O'Shaughnessy |
|
Group Director of Corporate Development | investor.relations@Uniphar.ie |
|
|
Davy | +353 (0) 1 679 6363 |
(Joint Corporate Broker, Nominated Adviser and Euronext Growth Adviser) |
|
|
|
Fergal Meegan |
|
Barry Murphy |
|
Niall Gilchrist |
|
|
|
RBC Capital Markets (Joint Corporate Broker) | +44 (0) 20 7653 4000 |
|
|
Jonathan Hardy |
|
Jamil Miah |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
Matt Blawat |
|
Ben Maddison |
|
Francis North |
|
|
|
Q4 PR | +353 (0) 1 475 1444 or |
(Public Relations Adviser to Uniphar) | +353 87 235 6461 |
|
|
Iarla Mongey |
|
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar plc ("Uniphar" and together with its subsidiaries the "Group") is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail.
With a workforce in excess of 2,600, the Group is active in Ireland, the UK, Benelux, the Nordics, and the US, delivering unlicensed and specialty medicine on a global basis.
The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.
Product Access
In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.